Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - AbbVie/Amgen/Byondis

Next Previous
Drug Profile

Trastuzumab biosimilar - AbbVie/Amgen/Byondis

Alternative Names: ABP-980; Herceptin biosimilar - Allergan/Amgen/Byondis; Kanjinti; Trastuzumab beta - Allergan/Amgen/Byondis; Trastuzumab-anns

Latest Information Update: 15 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synthon
  • Developer AbbVie; Amgen; Daiichi Sankyo Company
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer

Most Recent Events

  • 08 May 2020 Allergan has been acquired and merged into AbbVie
  • 16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
  • 01 Oct 2019 West German Study Group, Amgen, Merck Sharp & Dohme Corp. and NanoString Technologies plans a phase II trial in Breast cancer (Early stage disease, Neoadjuvant therapy, Combination therapy) with molecular HER2-enriched intrinsic subtype (IV) (NCT03988036)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top